Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology [0.03%]
黑色素瘤：皮肤类型指南建议中国版 2026 年第 2 版（NCCN 癌症临床实践指南）
Susan M Swetter,Douglas Johnson,Mark R Albertini et al.
Susan M Swetter et al.
The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma i...
The Evolving Clinical Utility of Gene Expression Profiling in Cutaneous Melanoma [0.03%]
基因表达谱在皮肤黑色素瘤中的临床应用价值越来越重要
Ahmad Rajeh,Maija Kiuru,Kelly Nelson et al.
Ahmad Rajeh et al.
Cutaneous melanoma risk assessment relies on clinicopathologic staging, which incompletely captures individual risk of nodal involvement, recurrence, and melanoma-specific mortality. Gene expression profiling (GEP) assays have been proposed...
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial [0.03%]
推进有针对性和帮助性的严重疾病对话的途径(PATH-SIC)：一项随机临床试验
Christopher R Manz,Cody E Cotner,Angela C Tramontano et al.
Christopher R Manz et al.
Background: Serious illness conversations (SICs) aim to elicit patient preferences and are associated with improved quality of life and reduced care utilization, but they occur infrequently. Sustainable interventions that...
Randomized Controlled Trial
Journal of the National Comprehensive Cancer Network : JNCCN. 2026 Jun;24(6):237-243. DOI:10.6004/jnccn.2025.7479 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026 [0.03%]
NCCN指南洞察：急性髓系白血病（版本3.2026）
Daniel A Pollyea,Jessica K Altman,Rita Assi et al.
Daniel A Pollyea et al.
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among ad...
Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use [0.03%]
癌症疼痛的布普品治疗：证据、指南和临床应用理據
Marcin Chwistek,Leigh Kinczewski,Sorin Buga et al.
Marcin Chwistek et al.
As cancer survivorship increases, long-term opioid therapy (LTOT) has become more common in oncology, raising concerns about opioid-related harms. Buprenorphine offers unique pharmacologic advantages that position it as a safer alternative ...
Daniel M Geynisman
Daniel M Geynisman
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study [0.03%]
基于UGT1A1基因型指导伊立替康剂量在真实世界中对严重毒性和住院影响的多中心研究
Niels Heersche,Sofía L J Peeters,Doortje Böhm et al.
Niels Heersche et al.
Background: Risk of irinotecan-related severe toxicity is significantly higher in patients carrying 2 dysfunctional UGT1A1 gene variants, characterized as poor metabolizers (PMs), following standard irinotecan dosing. Sin...
Feasibility and Efficacy of Reiki Versus Massage for Cancer-Related Fatigue in Patients With Breast and Prostate Cancer Receiving Hormone Therapy [0.03%]
替代疗法治疗癌症相关乏力的可行性及疗效：催能疗法 vs 按摩治疗乳腺癌和前列腺癌患者在接受激素治疗期间出现的癌症相关的乏力症状
Jeremy McGuire,Joseph Roscoe,Jennifer Reschke et al.
Jeremy McGuire et al.
Background: Cancer-related fatigue (CRF) is a common, distressing symptom in patients undergoing hormone therapy for breast and prostate cancer. Although exercise is recommended, it is not suitable for all patients. Passi...
Successful Management of BRAF V600E-Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy [0.03%]
恩考芬尼联合疗法成功治疗肝功能不全的BRAF V600E突变型转移性结直肠癌患者
Celine Hoyek,Angelo Pirozzi,Kelley Rone et al.
Celine Hoyek et al.
The recent approval of encorafenib, cetuximab, and FOLFOX based on the phase III BREAKWATER trial has introduced a new standard of care for the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer (mCRC). However, its saf...
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer [0.03%]
前列腺癌种族多样性队列中具有致病性的遗传变异体
Taylor B Crawford,Maliha Tayeb,Emanuel Barrett et al.
Taylor B Crawford et al.
Background: Pathogenic germline variant (PGV) rates in cancer risk genes and their association with clinicopathologic features inform genetic testing practices for patients with prostate cancer (PCa). In this study, we de...